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Clinical Pharmacology 
Pharmacokinetic and pharmacodynamic properties 
of inhaled corticosteroids in relation to efficacy 
and safety 
H. DERENDORF 
Department of Pharmaceutics, College of Pharmacy, University of Florida, U.S.A. 
There are significant differences in the pharmacokinetic properties of inhaled corticosteroids currently 
available for use in treatment of asthma and this can result in differences in pharmacodynamic activity. 
All currently used inhaled corticosteroids are rapidly cleared from the body, but show varying levels of 
oral bioavailability, with fluticasone propionate having the lowest. Following inhalation, there is also 
considerable variability in the rate of absorption from the lung, and pulmonary residence times are 
greatest for fluticasone propionate and triamcinolone acetonide, and shortest for budesonide and 
flunisolide. Cortisol suppression is frequently used as a surrogate marker of systemic corticosteroid 
activity. Cortisol release displays a circadian rhythm, which can be mathematically modelled and the 
effects of exogenous corticosteroids on cortisol suppression established. However, when interpreting the 
effects of inhaled corticosteroids on cumulative cortisol suppression, it is important to take into 
consideration the pharmacokinetic properties of each particular drug, together with the study design and 
the time of administration. 
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Introduction 
The delivery of corticosteroids via an inhaled rather 
than an oral route, together with the development 
and introduction of corticosteroids with higher thera- 
peutic ratios, has significantly improved the treatment 
of asthma. This improvement is mainly the result of 
better pharmacokinetic properties of corticosteroids. 
The ideal inhaled corticosteroid should have: pro- 
longed residence time in the lung; high intrinsic 
activity; low oral bioavailability and high systemic 
clearance (resulting in negligible systemic side effects). 
Immediately following inhalation via a metered- 
dose inhaler, lO-20% of the dose is deposited in the 
lung, whilst the majority (up to 90%) impacts on the 
oropharyngeal region and is swallowed (Fig. 1). Fol- 
lowing absorption from the gastrointestinal tract, the 
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drug passes through the liver before entry into the 
systemic circulation. Some corticosteroids, particu- 
larly budesonide and fluticasone propionate are 
metabolised (89%, 99% respectively; 1,2), during their 
first pass through the liver, and thus, following oral 
absorption enter the systemic circulation as inactive 
metabolites. Most drugs, however, are not efficiently 
inactivated during first-pass metabolism and are able 
to enter the systemic circulation unchanged, resulting 
in extra-pulmonary effects (most of which are 
unwanted). It is important to note that the dose 
delivered to the lung will also be absorbed into the 
systemic circulation. Absorption from the lung is 
rapid (3) and, since the drug is not usually metabo- 
lised locally, extra-pulmonary effects may occur, 
especially from very high inhaled doses (4). 
At present, five corticosteroids are available for use 
in the treatment of asthma: triamcinolone acetonide 
(TAA), flunisolide, beclomethasone dipropionate 
(BDP), budesonide, and fluticasone propionate. 
These inhaled corticosteroids differ not only in their 
pharmacokinetic properties, but also in their gluco- 
corticoid receptor affinity and potency (see Table 1). 
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FIG, 1. Schematic representation of the pharmacokinetic fate of inhaled corticosteroids. 
TABLE 1. Pharmacokinetic and pharmacodynamic parameters of inhaled corticosteroids 
Drug 
F OEll Finh 
(%I (“W 
Vdss 
(2) (El) CL) RRA 
Flunisolide 20 39 20 58 96 1.6 180 
Triamcinolone acetonide 23 22 29 37 103 2.0 233 
Budesonide 11 28 12 84 183 2.8 935 
Beclomethasone dipropionate 15 25 13 230 0.1 53 
Beclomethasone monopropionate - 1345 
Fluticasone propionate <I 16 10 69 318 7.8 1800 
Abbreviations: RRA = relative receptor affinity compared with dexamethasone (RRA = 100); f, = unbound 
fraction of the drug in plasma; CL = total body clearance; Vd,, = apparent volume of distribution at steady-state; 
tljl = plasma elimination half-life; Foral = oral bioavailability; Finh = inhalation bioavailability. 
For most of these corticosteroids, the pharmacologi- 
cally active form of the drug is inhaled. However, 
BDP is a prodrug which is activated by hydrolysis to 
the mono-ester, beclomethasone- 17-monopropionate 
(17-BMP). 
Bioavailability 
Inhaled corticosteroids are intended to provide their 
therapeutic effect at the site of delivery in the lung. In 
general, corticosteroids are absorbed well from the 
lung. However, as discussed previously, the greater 
part of an inhaled dose is swallowed and is therefore 
available for gastrointestinal absorption. Thus, the 
blood corticosteroid concentration represents the sum 
of pulmonary and orally absorbed fractions, and 
therefore separate assessment of the pulmonary bio- 
availability of those inhaled corticosteroids, that also 
undergo significant oral absorption, is difficult. Of the 
inhaled corticosteroids currently used in clinical prac- 
tice, the oral bioavailability of fluticasone propionate 
is the lowest with a value of less than 1% (5) com- 
pared with 23% for TAA (6), 20% for flunisolide (7) 
and 11% for budesonide (2). No reliable data are 
available for BDP. For fluticasone propionate, 
pulmonary bioavailability which can be calculated 
with greater assurance is l&30%, depending on the 
inhalation device used (8). Reported pulmonary bio- 
availabilities of other inhaled corticosteroids are: 22% 
for TAA (6), 39% for flunisolide (7) and 28% for 
budesonide (9). Data are unavailable for BDP. 
Plasma protein binding 
As only the free, unbound drug is able to interact 
with the glucocorticoid receptor, when measuring 
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plasma or serum concentrations of any of the inhaled 
corticosteroids, it is important to know the concen- 
tration of unbound drug. For the five inhaled corti- 
costeroids currently available, TAA has the lowest 
plasma protein binding (71%) (lo), followed by 
flunisolide (80%) (ll), budesonide (88%) (2), and 
fluticasone propionate (90%) (12). BDP has been 
reported to be 87% bound to plasma proteins (13), 
but no data are available for 17-BMP. 
Volume of distribution 
The volume of distribution (Vd) of an inhaled drug 
allows quantification of extra-pulmonary tissue distri- 
bution. The larger the Vd, the greater the amount of 
drug located in the peripheral tissues, but this does 
not necessarily indicate a higher systemic pharmaco- 
logical activity, as this depends on how much drug is 
distributed in bound/free form. The volume of distri- 
bution at steady state (Vd,,) for fluticasone propion- 
ate is 3 18 L (14), which is in agreement with the high 
lipophilicity of the drug. The Vd,, values for the other 
corticosteroids are reported to be 183 L for budeso- 
nide (15), 103 L for TAA (6), and 96 L for flunisolide 
(11). Again, no reliable data are available for BDP or 
17-BMP. 
Systemic clearance 
Rapid clearance following absorption should mini- 
mise the systemic side-effects of an inhaled drug. In 
theory, the faster the systemic clearance, the higher 
the therapeutic index. All of the currently used 
inhaled corticosteroids have rapid systemic clearances 
of similar magnitude: 37 L/h for TAA (6), 58 L/h for 
flunisolide (7), 84 L/h for budesonide (2), and 69 L/h 
for fluticasone propionate (14). These values are 
approximately the same as the rate of hepatic blood 
flow, which is the maximum clearance rate possible 
for hepatically metabolised drugs. BDP was reported 
to have a systemic clearance greater than hepatic 
blood flow (230 L/h), which is indicative of extra- 
hepatic metabolism (16). This value is expected for 
BDP as extra-hepatic metabolism results in the for- 
mation of the pharmacologically active metabolite, 
17-BMP. The clearance rate of 17-BMP has not been 
reported. 
Elimination half-life 
The elimination half-life of any drug is dependent on 
both the volume of distribution and the rate of 
systemic clearance. The elimination half-life quanti- 
fies bow rapidly the plasma concentration changes, 
but does not indicate the magnitude of concentration. 
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FIG. 2. Mean residence time (A) and mean 
absorption time (B) for triamcinolone acetonide 
(TAA), flunisolide (FLU), budesonide (BUD) and 
fluticasone propionate (FP). 
For the currently used inhaled corticosteroids, 
fluticasone propionate has the longest elimination 
half-life of 7-8 h (measured following intravenous 
administration), which is a result of its large volume 
of distribution (14). The elimination half-life of TAA 
is 2.0 h (6), flunisolide is 1.6 h (8,17), and budesonide 
is 2.8 h (2). The elimination half-life of BDP was 
recently reported to be only 0.1 h (18), but no data 
are available for 17-BMP. 
It is possible for the terminal half-life after inha- 
lation to differ from the elimination half-life after 
intravenous administration, if absorption from the 
lung is slow and is the overall rate limiting step. This 
may be the case for fluticasone propionate, since 
terminal half-life values of 10 h have been reported 
after inhalation. Since fluticasone propionate is 
absorbed only via the lung, this indicates a relatively 
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long residence time at the pulmonary site of action 
(Fig. 2). Similar results have been observed with 
TAA, where the terminal half-life after inhalation was 
also found to be longer (5.6 h) than after intravenous 
administration (2.7 h) (6). Terminal half-lifes of 
budesonide and flunisolide remain short after inha- 
lation, indicating rapid absorption both from the lung 
and from the gastrointestinal tract (2,19). The termi- 
nal half-life of 17-BMP is reported to be 6.5 h (18), 
but no reliable intravenous data are available to 
determine whether this value is limited by absorption. 
However, the limitation of this method of calculating 
terminal half-life is that it depends on the sensitivity 
of measurement of blood drug concentrations. Thus, 
low levels of drug in the lung may remain undetected, 
resulting in apparently low residence and absorption 
times. As with Vd, residence time in the lung is 
not necessarily directly related to pharmacological 
activity, as the latter depends on whether or not the 
drug is in the unbound, free form. However, a long 
residence time in the lung indicates a long-lasting 
availability for topical release and action. 
Accumulation 
Accumulation is the increase in plasma drug 
concentration that occurs during multiple-dose 
administration until steady-state is reached. The 
accumulation time is a function of the terminal 
elimination half-life of the drug, whereas the extent of 
accumulation, i.e. the magnitude of the steady-state 
plasma drug level, is independent of the half-life and 
is only a function of systemic clearance. Hence, it will 
take longer to reach steady-state for fluticasone pro- 
pionate than for budesonide, for example. However, 
for equal amounts of drug absorbed, the resulting 
steady-state concentrations will be quite similar 
(Fig. 3). 
Relative receptor affinity 
The receptor affinity of inhaled corticosteroids can be 
expressed relative to that of the standard, dexametha- 
sone (relative receptor affinity (RRA) = 100). Of the 
currently used corticosteroids, fluticasone propionate 
has the highest receptor affinity (RRA = 1800), 
followed by 17-BMP (RRA = 1345), budesonide 
(RRA = 935) TAA (RRA = 233) and flunisolide 
(RRA = 180) (Table 1; 20). These differences in affin- 
ity for the glucocorticoid receptor means that inhaled 
corticosteroids should never be compared based on 
microgram doses, but only in terms of equipotent 
doses. 
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FIG. 3. Simulated plasma concentrations of 
fluticasone propionate (FP) and budesonide (BUD) 
after inhalation of a 1 mg-dose twice daily (inhaled 
bioavailability 25%). 
Pharmacokinetic-pharmacodynamic profiles 
Cortisol suppression is the most frequently used 
surrogate marker of systemic activity of corticoster- 
oids. However, cortisol release follows a circadian 
rhythm, which makes analysis of corticosteroid- 
induced cortisol suppression very complex. It is poss- 
ible to use deconvolution methods to convert cortisol 
concentrations into cortisol release rates, which can 
then be described by a set of two straight-line equa- 
tions (21). This model is able to describe cortisol 
baseline data, and furthermore, can account for cor- 
tisol suppression by exogenous corticosteroids using 
the equation below: 
where C,,,, is the cortisol concentration, R, is the 
cortisol release rate [concentration/time], E,,, is 
the maximum possible effect (usually l), E,, is the 
unbound concentration of the exogenous corticoster- 
oid that produces 50% of the maximum effect, k, is 
the elimination rate constant of cortisol, and t is 
time (21). The measured and curve-fitted cortisol 
concentrations after pulmonary administration of 
flunisolide (19), TAA (10) and fluticasone propionate 
(8) are shown in Figure 4. The cumulative extent of 
suppression, for example over 24 hours, can be 
expressed as the area between the baseline and the 
suppressed cortisol levels. This pharmacokinetic- 
pharmaco dynamic model allows good prediction of 
measured cumulative cortisol suppression as reported 
in several published studies (Fig. 5) (22). 
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FIG. 5. Correlation between predicted cumulative 
cortisol suppression (CCS) as a percent of baseline 
and measured CCS for triamcinolone acetonide 
(TAA), flunisolide (FLU) and fluticasone 
propionate (FP) in several clinical studies. Values 
are expressed as mean * SD (where available). 
When examining the suppressive effects of inhaled 
corticosteroids on cortisol release, it is also important 
to consider the time of drug administration in view of 
the circadian rhythm of cortisol release. A compari- 
son of the calculated cumulative cortisol suppression 
after administration of inhaled flunisolide 1000 ug 
and fluticasone propionate 500 ug at either 0800 or 
2000 h (23) is shown in Figure 6. As can be seen for 
flunisolide, a drug with a comparatively short elimi- 
nation half-life, administration at 2000 h produces 
less cortisol suppression than at 0800 h, whereas for 
fluticasone propionate, which has a longer elimi- 
nation half-life, there is no significant difference in 
cortisol suppression between morning and evening 
administration. It is extremely i,mportant, therefore, 
to critically examine the study design and drug 
administration time when evaluating and comparing 
results between such studies. 
Discussion 
Examination of the pharmacokinetic and pharmaco- 
dynamic properties of currently available inhaled 
corticosteroids reveals significant differences. While 
most show rapid systemic clearance after absorption, 
FIG. 4. Plasma cortisol concentrations (mean f SD) 
after inhalation of 1 mg flunisolide (A), 2 mg 
triamcinolone acetonide (B) and 1 mg fluticasone 
propionate (C). Also shown is the respective cortisol 
baseline profile (dotted line). 
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FIG. 6. Cumulative cortisol suppression over 
24 hours following administration of either inhaled 
flunisolide 1000 pg or fluticasone propionate 500 pg 
at 0800 or 2000 h. 
there are differences in oral bioavailability and 
absorption rate from the lung following inhalation. 
The lung absorption rate is an important property, as 
it reflects the pulmonary residence time, and there- 
fore, duration of availability of the drug in the lung. 
Long residence times have been calculated for fluti- 
casone propionate and TAA, whereas budesonide 
and flunisolide are absorbed very rapidly from the 
lung. Mathematical analysis of the suppressive effects 
of inhaled corticosteroids on cortisol levels has 
revealed that the pharmacokinetic properties of the 
drugs are responsible for some of the effects observed. 
Further understanding of the underlying mechanisms 
of asthma may improve the therapeutic index of 
corticosteroids in the future. 
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